|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CORO1C |
Gene summary for CORO1C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CORO1C | Gene ID | 23603 |
| Gene name | coronin 1C | |
| Gene Alias | HCRNN4 | |
| Cytomap | 12q24.11 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9ULV4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23603 | CORO1C | LZE2T | Human | Esophagus | ESCC | 3.22e-02 | 3.21e-01 | 0.082 |
| 23603 | CORO1C | LZE4T | Human | Esophagus | ESCC | 5.24e-14 | 4.73e-01 | 0.0811 |
| 23603 | CORO1C | LZE5T | Human | Esophagus | ESCC | 1.88e-04 | -1.09e-01 | 0.0514 |
| 23603 | CORO1C | LZE8T | Human | Esophagus | ESCC | 3.77e-03 | 2.02e-01 | 0.067 |
| 23603 | CORO1C | LZE22T | Human | Esophagus | ESCC | 2.61e-09 | 2.54e-01 | 0.068 |
| 23603 | CORO1C | LZE24T | Human | Esophagus | ESCC | 4.27e-12 | 3.33e-01 | 0.0596 |
| 23603 | CORO1C | LZE6T | Human | Esophagus | ESCC | 1.37e-06 | -3.52e-02 | 0.0845 |
| 23603 | CORO1C | P1T-E | Human | Esophagus | ESCC | 2.94e-02 | 1.16e-01 | 0.0875 |
| 23603 | CORO1C | P2T-E | Human | Esophagus | ESCC | 3.50e-17 | 4.27e-01 | 0.1177 |
| 23603 | CORO1C | P4T-E | Human | Esophagus | ESCC | 8.33e-15 | 5.51e-01 | 0.1323 |
| 23603 | CORO1C | P5T-E | Human | Esophagus | ESCC | 5.02e-24 | 4.94e-01 | 0.1327 |
| 23603 | CORO1C | P8T-E | Human | Esophagus | ESCC | 2.85e-11 | 1.84e-01 | 0.0889 |
| 23603 | CORO1C | P9T-E | Human | Esophagus | ESCC | 2.66e-12 | 2.21e-01 | 0.1131 |
| 23603 | CORO1C | P10T-E | Human | Esophagus | ESCC | 2.51e-13 | -1.47e-02 | 0.116 |
| 23603 | CORO1C | P11T-E | Human | Esophagus | ESCC | 4.91e-16 | 4.76e-01 | 0.1426 |
| 23603 | CORO1C | P12T-E | Human | Esophagus | ESCC | 2.11e-19 | 4.40e-01 | 0.1122 |
| 23603 | CORO1C | P15T-E | Human | Esophagus | ESCC | 4.28e-20 | 5.45e-01 | 0.1149 |
| 23603 | CORO1C | P16T-E | Human | Esophagus | ESCC | 1.30e-10 | 2.41e-01 | 0.1153 |
| 23603 | CORO1C | P17T-E | Human | Esophagus | ESCC | 3.52e-02 | 4.49e-01 | 0.1278 |
| 23603 | CORO1C | P20T-E | Human | Esophagus | ESCC | 6.63e-23 | 6.58e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009013216 | Prostate | BPH | epithelium migration | 104/3107 | 360/18723 | 2.96e-09 | 1.15e-07 | 104 |
| GO:009013016 | Prostate | BPH | tissue migration | 105/3107 | 365/18723 | 3.21e-09 | 1.24e-07 | 105 |
| GO:001063116 | Prostate | BPH | epithelial cell migration | 103/3107 | 357/18723 | 3.80e-09 | 1.44e-07 | 103 |
| GO:001076916 | Prostate | BPH | regulation of cell morphogenesis involved in differentiation | 40/3107 | 96/18723 | 5.08e-09 | 1.86e-07 | 40 |
| GO:000166717 | Prostate | BPH | ameboidal-type cell migration | 128/3107 | 475/18723 | 5.69e-09 | 2.05e-07 | 128 |
| GO:003444616 | Prostate | BPH | substrate adhesion-dependent cell spreading | 43/3107 | 108/18723 | 7.20e-09 | 2.50e-07 | 43 |
| GO:000195210 | Prostate | BPH | regulation of cell-matrix adhesion | 48/3107 | 128/18723 | 9.98e-09 | 3.34e-07 | 48 |
| GO:001063216 | Prostate | BPH | regulation of epithelial cell migration | 87/3107 | 292/18723 | 1.18e-08 | 3.87e-07 | 87 |
| GO:003432910 | Prostate | BPH | cell junction assembly | 114/3107 | 420/18723 | 2.52e-08 | 7.49e-07 | 114 |
| GO:000193317 | Prostate | BPH | negative regulation of protein phosphorylation | 97/3107 | 342/18723 | 2.74e-08 | 8.11e-07 | 97 |
| GO:000716010 | Prostate | BPH | cell-matrix adhesion | 72/3107 | 233/18723 | 4.17e-08 | 1.16e-06 | 72 |
| GO:190002416 | Prostate | BPH | regulation of substrate adhesion-dependent cell spreading | 27/3107 | 57/18723 | 6.30e-08 | 1.67e-06 | 27 |
| GO:00313469 | Prostate | BPH | positive regulation of cell projection organization | 98/3107 | 353/18723 | 7.34e-08 | 1.88e-06 | 98 |
| GO:005134818 | Prostate | BPH | negative regulation of transferase activity | 78/3107 | 268/18723 | 1.94e-07 | 4.29e-06 | 78 |
| GO:19018888 | Prostate | BPH | regulation of cell junction assembly | 62/3107 | 204/18723 | 6.71e-07 | 1.30e-05 | 62 |
| GO:00160507 | Prostate | BPH | vesicle organization | 82/3107 | 300/18723 | 1.64e-06 | 2.78e-05 | 82 |
| GO:00071628 | Prostate | BPH | negative regulation of cell adhesion | 82/3107 | 303/18723 | 2.51e-06 | 4.04e-05 | 82 |
| GO:000646916 | Prostate | BPH | negative regulation of protein kinase activity | 62/3107 | 212/18723 | 2.81e-06 | 4.45e-05 | 62 |
| GO:003367315 | Prostate | BPH | negative regulation of kinase activity | 67/3107 | 237/18723 | 4.15e-06 | 6.25e-05 | 67 |
| GO:19027439 | Prostate | BPH | regulation of lamellipodium organization | 23/3107 | 54/18723 | 5.78e-06 | 8.47e-05 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CORO1C | SNV | Missense_Mutation | c.803C>T | p.Ala268Val | p.A268V | Q9ULV4 | protein_coding | tolerated(0.08) | benign(0.052) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CORO1C | SNV | Missense_Mutation | c.374N>G | p.Ser125Cys | p.S125C | Q9ULV4 | protein_coding | deleterious(0.03) | benign(0.049) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CORO1C | SNV | Missense_Mutation | c.1531N>G | p.Gln511Glu | p.Q511E | Q9ULV4 | protein_coding | deleterious(0.04) | benign(0.127) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CORO1C | SNV | Missense_Mutation | c.1323N>G | p.Ile441Met | p.I441M | Q9ULV4 | protein_coding | tolerated(0.54) | benign(0.092) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| CORO1C | SNV | Missense_Mutation | novel | c.106N>A | p.His36Asn | p.H36N | Q9ULV4 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-E9-A5UO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CORO1C | insertion | In_Frame_Ins | novel | c.938_939insCAGACTTGTCTCTGGTTTCTTACAGGGTGACAGCAGTAT | p.His313_Glu314insArgLeuValSerGlyPheLeuGlnGlyAspSerSerIle | p.H313_E314insRLVSGFLQGDSSI | Q9ULV4 | protein_coding | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| CORO1C | insertion | Nonsense_Mutation | novel | c.1256_1257insTAAATGAAGATAAGATATTTATTCCATCCATGTAT | p.Gly420LysfsTer2 | p.G420Kfs*2 | Q9ULV4 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| CORO1C | SNV | Missense_Mutation | novel | c.59N>A | p.Arg20His | p.R20H | Q9ULV4 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CORO1C | SNV | Missense_Mutation | rs762661543 | c.1270N>A | p.Ala424Thr | p.A424T | Q9ULV4 | protein_coding | deleterious(0.01) | possibly_damaging(0.742) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CORO1C | SNV | Missense_Mutation | c.790N>A | p.Glu264Lys | p.E264K | Q9ULV4 | protein_coding | deleterious(0.01) | possibly_damaging(0.479) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |